Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dustin Shilling

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Hematology/Oncology Clinics of North America|November 22, 2017
Castleman Disease PathogenesisDavid C Fajgenbaum, Dustin Shilling
Emerging Topics in Life Sciences|February 1, 2021
The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseasesMary Zuccato, Dustin Shilling, David C Fajgenbaum
The Journal of Biological Chemistry|February 8, 2012
Lack of evidence for presenilins as endoplasmic reticulum Ca2+ leak channelsDustin Shilling, Don-On Daniel Mak, David E Kang, et al.
Circulation Research|September 18, 2007
Sphingosine 1-phosphate receptor 2 negatively regulates neointimal formation in mouse arteriesTakuya Shimizu, Tatsu Nakazawa, Aesim Cho, et al.
Journal of Vascular Surgery|October 2, 2007
Regulation of arterial lesions in mice depends on differential smooth muscle cell migration: a role for sphingosine-1-phosphate receptorsShinya Inoue, Tatsu Nakazawa, Aesim Cho, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 16, 2014
Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesisDustin Shilling, Marioly Müller, Hajime Takano, et al.
British Journal of Haematology|September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial dataDeanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
American Journal of Hematology|April 21, 2018
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman diseaseSheila K Pierson, Aaron J Stonestrom, Dustin Shilling, et al.
Cell Host & Microbe|January 22, 2013
A host GPCR signaling network required for the cytolysis of infected cells facilitates release of apicomplexan parasitesMelanie G Millholland, Satish Mishra, Christopher D Dupont, et al.
Plos One|June 27, 2019
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseaseChristopher S Nabel, Stephen Sameroff, Dustin Shilling, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Hematology/Oncology Clinics of North America|November 22, 2017
Castleman Disease PathogenesisDavid C Fajgenbaum, Dustin Shilling
Emerging Topics in Life Sciences|February 1, 2021
The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseasesMary Zuccato, Dustin Shilling, David C Fajgenbaum
The Journal of Biological Chemistry|February 8, 2012
Lack of evidence for presenilins as endoplasmic reticulum Ca2+ leak channelsDustin Shilling, Don-On Daniel Mak, David E Kang, et al.
Circulation Research|September 18, 2007
Sphingosine 1-phosphate receptor 2 negatively regulates neointimal formation in mouse arteriesTakuya Shimizu, Tatsu Nakazawa, Aesim Cho, et al.
Journal of Vascular Surgery|October 2, 2007
Regulation of arterial lesions in mice depends on differential smooth muscle cell migration: a role for sphingosine-1-phosphate receptorsShinya Inoue, Tatsu Nakazawa, Aesim Cho, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 16, 2014
Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesisDustin Shilling, Marioly Müller, Hajime Takano, et al.
British Journal of Haematology|September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial dataDeanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
American Journal of Hematology|April 21, 2018
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman diseaseSheila K Pierson, Aaron J Stonestrom, Dustin Shilling, et al.
Cell Host & Microbe|January 22, 2013
A host GPCR signaling network required for the cytolysis of infected cells facilitates release of apicomplexan parasitesMelanie G Millholland, Satish Mishra, Christopher D Dupont, et al.
Plos One|June 27, 2019
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseaseChristopher S Nabel, Stephen Sameroff, Dustin Shilling, et al.
Pageof 2